Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Fabrazyme
Active Ingredient: Agalsidase beta - rch 37mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Medra Services Limited
Manufacturer(s): Genzyme Corporation, Allston, Massachusetts, United States of America
Genzyme Corporation, Framingham, Massachusetts, United States of America
Note: This consent is valid for 2 years from the date of publication of this notice.
Dated this 16th day of January 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).